Abstract: Provided herein are transgenic non-human animals whose genomes comprise two or more human genes selected from CD33, Siglec-5, Siglec-7, Siglec-9, Siglec-11, Siglec-14, and Siglec-16, to methods of screening candidate agents that bind to and/or modulate the function and/or activity of at least one of the human genes in the transgenic non-human animals, and to methods of screening candidate agents to determine their effect on one or more activities and/or functions associated with expression of at least one of the human genes in the transgenic non-human animals. Further provided herein are methods of recapitulating a human Siglec immune system in a non-human animal, and methods of generating a non-human animal disease model comprising a human Siglec repertoire.
Abstract: The present disclosure is generally directed to Siglec-9 ECDs and Siglec-9 ECD fusion molecules, and methods of treatment using Siglec-9 ECDs and Siglec-9 ECD fusion molecules.
Abstract: The present disclosure is generally directed to the use of compositions that include antibodies, e.g., monoclonal, chimeric, affinity-matured or humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a Sortilin protein, e.g., human Sortilin or mammalian Sortilin, and have improved and/or enhanced functional characteristics, in treating and/or delaying progression of a disease or injury in an individual in need thereof.
Type:
Application
Filed:
December 7, 2023
Publication date:
April 25, 2024
Applicant:
Alector LLC
Inventors:
Robert PAUL, Sam JACKSON, Omer Rizwan SIDDIQUI, Michael F. WARD, Felix Leejia YEH, Julie Y. HUANG, Whedy WANG, Yijie LIAO, Brian C. MANGAL
Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Siglec-5 protein, e.g., human Siglec-5 or a mammalian Siglec-5, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
Type:
Grant
Filed:
May 9, 2022
Date of Patent:
April 23, 2024
Assignee:
Alector LLC
Inventors:
Kate Monroe, Helen Lam, Patricia Culp, Arnon Rosenthal
Abstract: The present disclosure is generally directed to the use of antibodies that specifically bind one or more epitopes within a sortilin protein, e.g., human sortilin or mammalian sortilin, for treating and/or delaying progression of a disease, disorder, or injury in an individual in need thereof.
Type:
Application
Filed:
December 1, 2021
Publication date:
March 28, 2024
Applicant:
Alector LLC
Inventors:
Arnon ROSENTHAL, Felix Leejia YEH, Michael F. WARD, Robert PAUL, Hua LONG, Yijie LIAO
Abstract: The invention provides anti-SIRPA antibodies, methods of generating such antibodies, and therapeutic uses and methods employing the antibodies.
Type:
Application
Filed:
August 23, 2023
Publication date:
March 14, 2024
Applicant:
Alector LLC
Inventors:
Andrew Pincetic, Arnon Rosenthal, Seung-Joo Lee
Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Siglec-9 protein, e.g., human Siglec-9 or a mammalian Siglec-9, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
Type:
Application
Filed:
April 10, 2023
Publication date:
February 29, 2024
Applicant:
Alector LLC
Inventors:
Arnon Rosenthal, Kate Monroe, Seung-Joo Lee
Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a MerTK polypeptide, e.g., a mammalian MerTK or human MerTK, and use of such compositions in treating an individual in need thereof.
Abstract: The invention provides anti-SIRPA antibodies, methods of generating such antibodies, and therapeutic uses and methods employing the antibodies.
Type:
Grant
Filed:
December 8, 2017
Date of Patent:
October 10, 2023
Assignee:
Alector LLC
Inventors:
Andrew Pincetic, Arnon Rosenthal, Seung-Joo Lee
Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind a TREM2 protein, e.g., a mammalian TREM2 or human TREM2, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
Type:
Application
Filed:
February 17, 2023
Publication date:
September 21, 2023
Applicant:
Alector LLC
Inventors:
Tina SCHWABE, Fracesca AVOGADRI-CONNORS, Helen LAM, Ilaria TASSI, Seung-Joo LEE, Arnon ROSENTHAL
Abstract: The present disclosure is generally directed to the use of compositions that include antibodies, e.g., monoclonal, chimeric, affinity-matured, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a TREM2 protein, e.g., human TREM2, for use in treating and/or delaying progression of a disease or injury in an individual in need thereof.
Type:
Application
Filed:
April 2, 2021
Publication date:
June 15, 2023
Applicant:
Alector LLC
Inventors:
Robert PAUL, Michael F. WARD, Hua LONG, Omer Rizwan SIDDIQUI, Arnon ROSENTHAL, Felix Leejia YEH, Sam JACKSON
Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a Siglec-9 protein, e.g., human Siglec-9 or a mammalian Siglec-9, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
Type:
Grant
Filed:
September 10, 2020
Date of Patent:
June 6, 2023
Assignee:
Alector LLC
Inventors:
Arnon Rosenthal, Kate Monroe, Seung-Joo Lee
Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal antibodies, humanized antibodies and antibody fragments, that specifically bind a MS4A4A polypeptide, e.g., a mammalian MS4A4A or human MS4A4A, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
Type:
Grant
Filed:
July 30, 2020
Date of Patent:
June 6, 2023
Assignee:
Alector LLC
Inventors:
Jeonghoon Sun, Wei-Hsien Ho, Muhammad A. Alhawagri, Philip Ling Kong, Herve Rhinn, Hua Long, Karpagam Srinivasan, Ananya Mitra, Daniel P. Bermingham, Klaus-Dieter Heger, Santiago Viveros Salazar, Francesca Cignarella, Ilaria Tassi, Tina Schwabe, Angie Grace Yee, Arnon Rosenthal
Abstract: The present disclosure is generally directed to the use of anti-TREM2 antibodies in preventing, reducing risk, or treating disease in an individual in need thereof.
Type:
Application
Filed:
February 23, 2021
Publication date:
May 25, 2023
Applicants:
Alector LLC, Washington University
Inventors:
Francesca CIGNARELLA, Fabia FILIPELLO, Bryan BOLLMAN, Arnon ROSENTHAL, Tina SCHWABE, Ilaria TASSI, Laura PICCIO
Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a TREM2 protein, e.g., a mammalian TREM2 or human TREM2, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
Type:
Grant
Filed:
March 30, 2020
Date of Patent:
April 25, 2023
Assignee:
Alector LLC
Inventors:
Tina Schwabe, Eric Brown, Philip Kong, Ilaria Tassi, Seung-Joo Lee, Arnon Rosenthal, Robert Pejchal, Nels P. Nielson
Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind a TREM1 protein, e.g., a mammalian TREM1 or human TREM1, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
Type:
Application
Filed:
September 13, 2022
Publication date:
April 20, 2023
Applicant:
Alector LLC
Inventors:
Andrew Pincetic, Arnon Rosenthal, Helen Lam, Francesca Avogadri-Connors, Seung-Joo Lee
Abstract: The invention is generally directed to methods and compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind a TREM2 protein, e.g., a mammalian TREM2 and/or human TREM2. The methods provided herein find use in preventing, reducing risk, or treating an individual having dementia, frontotemporal dementia, Alzheimer's disease, Nasu-Hakola disease, or multiple sclerosis.
Type:
Application
Filed:
April 21, 2022
Publication date:
April 6, 2023
Applicant:
Alector LLC
Inventors:
Kate MONROE, Tina SCHWABE, Francesca AVOGADRI-CONNORS, Ilaria TASSI, Helen LAM, Arnon ROSENTHAL
Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, affinity-matured, humanized antibodies, antibody fragments, etc., that specifically bind a Sortilin protein, e.g., human Sortilin or mammalian Sortilin, and have improved and/or enhanced functional characteristics, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
Type:
Application
Filed:
June 9, 2022
Publication date:
February 16, 2023
Applicant:
Alector LLC
Inventors:
Tina SCHWABE, Michael KURNELLAS, Arnon ROSENTHAL, Robert PEJCHAL, Anthony B. COOPER
Abstract: The present disclosure is generally directed to antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a CD33 protein, e.g., human CD33 or a mammalian CD33, and have improved and/or enhanced functional characteristics. The present disclosure is further directed to the methods of treating and/or delaying the progression of a disease or injury in an individual by administering such antibodies.
Type:
Application
Filed:
December 11, 2020
Publication date:
February 2, 2023
Applicant:
Alector LLC
Inventors:
Robert PAUL, Michael F. WARD, Hua LONG, Shiao-Ping LU, Omer Rizwan SIDDIQUI, Arnon ROSENTHAL
Abstract: The present disclosure is generally directed to the use of anti-TREM2 antibodies in preventing, reducing risk, or treating disease in an individual in need thereof.
Type:
Application
Filed:
December 4, 2020
Publication date:
January 26, 2023
Applicant:
Alector LLC
Inventors:
Tina SCHWABE, Ilaria TASSI, Arnon ROSENTHAL, Hua LONG, Santiago Viveros SALAZAR